Team:LZU-CHINA

Loading...
Welcome to our web page~
If you are using MS IE, Edge, or some old browsers, something bizarre may happens
Pancreatic cancer is called "the king of cancer" The hardest to solve
Pancreatic cancer is a malignant tumor of the digestive tract that is highly malignant and difficult to diagnose and treat. Early diagnosis and treatment are the key to improving the prognosis of pancreatic cancer. In our project, we have designed a system that can produce different responses by judging the current state of the cell to solve this problem.
We use a regulatory line of protein-protein interactions to achieve this target. The protein loop has a more rapid regulation and more direct coupling to the endogenous signaling pathway, and can directly deliver protease mRNA into the target cell without integrating the gene into the target cell genome.
click the TIL cell to open/close its details~
We extracted TIL cells from the patient's cancer cells and injected the engineered TIL cells back into the patient. TIL cells can target tumor masses where cancer cells localize and function, and exosomes automatically encapsulate mRNA and send it to cancer cells. This allows us to take different responses depending on the current state of the cell. If the cells are healthy, then the system will not start, so as to avoid harming normal cells to the greatest extent; if only a few cells are cancerous, the system will increase the amount of ALKBH5 through the ras-raf pathway receptor to attenuate the expression of the wnt pathway. Thereby inhibiting proliferation and invasion and metastasis; if a large number of cells have undergone cancer, the system will initiate an apoptosis program through the hypoxia-inducible factor system, releasing a large amount of casp3 to promote apoptosis of cancer cells.
Our system is designed to play a large role in the early treatment of pancreatic cancer and is also desirable in the treatment of other cancers.
Protein-protein loop
The protein loop has a more rapid regulation and more direct coupling to the endogenous signaling pathway, and can directly deliver protease mRNA into the target cell without integrating the gene into the target cell genome. We engineered TIL cells to deliver protease mRNA directly into the cells of interest.
Targeted
We designed two systems for diffused tumor cells and tumor cells infiltrated into tissues. It is inhibited or killed depending on the difference between the two cells.
Safety
TWe have designed two sets of sensory systems to ensure that different treatments can be performed depending on the patient's different conditions to avoid damage to the body caused by over-treatment, while a protein-decoding peptide is linked to a protein that exerts a killing effect in the effector system. This will minimize damage to normal cells.
Prognosis treatment
On the basis of conventional surgical resection of tumors, TIL cells extracted from cancer cells of patients are modified, and engineered TIL cells are injected back into the patient. Early treatment for early cancer, combined with surgical treatment for advanced cancer can effectively improve the survival rate after surgery.
Future prospects
We want to use the DBTL (design, build, test, lean) loop to find a reasonable segmentation site for ALKBH5. This will make our project more feasible.

Medal Criterion

√1. We have expanded on our silver medal activity by demonstrating how we have integrated the investigated issues into the purpose, design, and/or execution of our project. See our Human Practices page here

√2. Improve the function of an existing BioBrick Part here

√3. Our project's design and/or implementation is based on insight we have gained from modeling. See our model page here

√4. Demonstration: To convince the judges that our engineered system works. Of course we can! here

√ 1. One new BioBrick Part (Basic or Composite, must be RFC10 compatible) of our own design that is related to our project works as expected. Clearly document the experimental characterization on that Part's Main Page on the Registry. We have submitted ? BioBrick Parts：

√ 2. We have significantly worked with more than one currently registered 2019 iGEM teams in a meaningful way. See our Collaborations page here

√ 3. We have thought carefully and creatively about whether your work is responsible and good for the world. See our Human Practice page here

√ 1. Register for iGEM, have a great iGEM season, and attend the Giant Jamboree.

√ 2. Meet all deliverables on the Requirements page (wiki, poster, Presentation and judging form)

√ 3. Attributions: We have created a page on our team wiki with clear attribution of each aspect of our project. See our page here

√ 4. Project Inspiration and Description: On our Project Description page, we document how and why we chose our iGEM project, and how we achieve our goal here

√5. We have added quantitative experimental characterization data to an existing Part from the Registry of Standard Biological Parts. here